CEO Lishan Aklog Reports 5.1% Beneficial Ownership in PAVmed Following Significant Restricted Stock Grant

summarizeSummary

PAVmed's Chairman and CEO, Lishan Aklog, M.D., reported beneficial ownership of 5.1% of the company's common stock, primarily due to a recent grant of 350,000 restricted shares.

check_boxKey Events

• CEO Becomes 5.1% Beneficial Owner

  Dr. Lishan Aklog, Chairman and CEO, reported beneficial ownership of 369,068 shares, representing 5.1% of PAVmed's common stock.

• Significant Restricted Stock Grant

  The increase in ownership is primarily due to a grant of 350,000 restricted shares to Dr. Aklog on April 2, 2026, as compensation for services. This grant is valued at approximately $3.5 million.

• Long-Term Vesting Schedule

  These newly granted restricted shares are subject to a vesting schedule, with a single vesting date of May 20, 2029, incentivizing long-term performance.

• No Immediate Corporate Changes Planned

  The filing states that Dr. Aklog has no current plans for extraordinary corporate transactions, changes in management, or material shifts in capitalization or dividend policy.

auto_awesomeAnalysis

This Schedule 13D filing reveals that PAVmed's Chairman and CEO, Lishan Aklog, M.D., has become a 5.1% beneficial owner of the company's common stock, largely driven by a substantial grant of 350,000 restricted shares on April 2, 2026. This significant equity award, valued at approximately $3.5 million based on the current stock price, strongly aligns the CEO's long-term interests with shareholder value, especially as these shares vest over time (May 2029). The filing also confirms Dr. Aklog has no immediate plans for extraordinary corporate transactions or changes to the company's structure, providing a degree of stability. This increased insider ownership comes shortly after the company's 10-K disclosed a going concern warning and recent dilutive capital raises, suggesting a continued commitment from leadership during a critical period for the company.